Clinical Trial Update: Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab alone and in combination with acalabrutinib in advanced non-small cell lung cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2019-09-12